Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation and Depletion (2020 - 2022)

Protagonist Therapeutics' Depreciation and Depletion history spans 3 years, with the latest figure at $254000.0 for Q4 2022.

  • For Q4 2022, Depreciation and Depletion rose 8.09% year-over-year to $254000.0; the TTM value through Dec 2022 reached $1.0 million, up 26.94%, while the annual FY2025 figure was $1.2 million, 37.02% up from the prior year.
  • Depreciation and Depletion for Q4 2022 was $254000.0 at Protagonist Therapeutics, down from $270000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $270000.0 in Q3 2022 and bottomed at $180000.0 in Q1 2021.
  • The 3-year median for Depreciation and Depletion is $235000.0 (2021), against an average of $225888.9.
  • The largest YoY upside for Depreciation and Depletion was 40.0% in 2022 against a maximum downside of 8.09% in 2022.
  • A 3-year view of Depreciation and Depletion shows it stood at $188000.0 in 2020, then increased by 25.0% to $235000.0 in 2021, then increased by 8.09% to $254000.0 in 2022.
  • Per Business Quant, the three most recent readings for PTGX's Depreciation and Depletion are $254000.0 (Q4 2022), $270000.0 (Q3 2022), and $259000.0 (Q2 2022).